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The Nutrition Society Annual Summer meeting hosted by Newcastle University was held on 15–18 July 2013
Conference on ‘Nutrition and healthy ageing’
Symposium 3: Nutrition modulation of the ageing trajectory
Can resveratrol help to maintain metabolic health?
Patrick Schrauwen* and Silvie Timmers
Department of Human Biology, Maastricht University Medical Center, NUTRIM School for Nutrition,
Toxicology and Metabolism, P.O. Box 616, NL-6200 MD Maastricht, The Netherlands
The number of people suffering from metabolic diseases is dramatically increasing
worldwide. This stresses the need for new therapeutic strategies to combat this growing epi-
demic of metabolic diseases. A reduced mitochondrial function is one of the characteristics
of metabolic diseases and therefore a target for intervention. Here we review the evidence
that mitochondrial function may act as a target to treat and prevent type 2 diabetes mellitus,
and, if so, whether these effects are due to reduction in skeletal muscle fat accumulation. We
describe howexercisemay affect these parameters and can be beneficial for type 2 diabetes.We
next focus on alternative ways to improve mitochondrial function in a non-exercise manner.
Thus, in 2003, resveratrol (3,5,4′-trihydroxystilbene) was discovered to be a small molecule ac-
tivator of sirtuin 1, an important molecular target regulating cellular energy metabolism
and mitochondrial homoeostasis. Rodent studies have clearly demonstrated the potential of
resveratrol to improve various metabolic health parameters. Here we review data in human
subjects that is available on the effects of resveratrol on metabolism and mitochondrial func-
tion and discuss how resveratrol may serve as a new therapeutic strategy to preserve metabolic
health. We also discuss whether the effects of resveratrol are similar to the effects of exercise
training and therefore if resveratrol can be considered as an exercise mimetic.
Resveratrol: Ageing: Metabolic health: Mitochondria: Human subjects
Westernised society is confronted with major challenges
to combat chronic metabolic diseases, whose prevalence
are on the rise. Even though human subjects are living
longer, this increased longevity is also accompanied
by increased prevalence of chronic diseases, such as
type 2 diabetes mellitus (T2DM) and CVD. Therefore,
the challenge for the upcoming years will not only be
to increase lifespan, but also to age healthily. In that re-
spect, another major challenge will be to combat the
prevalence of obesity, as nowadays ∼50% of the popu-
lation is overweight or obese. In fact, obesity is well
known to increase the risk of metabolic diseases such
as T2DM and CVD.
We and others have shown that obesity is associated
with the accumulation of fat not only in white adipose
tissue, but excessive fat is also stored is so-called ectopic
sites, such as skeletal muscle, liver and the heart(1–5). In
these tissues, accumulation of intracellular lipid is asso-
ciated with cellular dysfunction, including cellular insulin
resistance. The latter is one of the earliest hallmarks in
the development of T2DM, and therefore ectopic fat sto-
rage has been thought to be a causal factor in the devel-
opment of diabetes. Importantly, insulin sensitivity is
also known to decline with ageing(6). Petersen et al.
showed that whole-body and muscle-specific insulin sen-
sitivity was reduced in elderly compared with young sub-
jects, and was accompanied by elevated intramyocellular
lipid (IMCL) content(7). Interestingly, Wijsman et al.(8)
reported previously that offspring from long-lived sib-
lings, participants in the Leiden Longevity study, were
characterised by higher peripheral, specifically skeletal
muscle, insulin sensitivity when compared with control
subjects. Recently, this finding was extended by showing
that IMCL content, measured by 1H-magnetic resonance
spectroscopy, was reduced in these offspring, further il-
lustrating that maintaining insulin sensitivity and keep-
ing ectopic fat accumulation low may be important
factors that determine longevity(9).
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Does a reduced mitochondrial function underlie
ectopic fat storage?
Accumulation of fat in ectopic fat depots is in essence
due to a disbalance between fat uptake and oxidation. Re-
search over the past two decades has revealed that both
obese and insulin-resistant subjects as well as T2DM
patients are characterised by a decreased capacity to oxi-
dise fatty acids(10,11). Initially, this reduced fat oxidative
capacity was pinpointed to be the result of reduced ac-
tivity by oxidative enzymes in skeletal muscle in patients
with T2DM(12,13). In the past decade, focus has shifted
towards mitochondrial function as the underlying cause
for reduced fat oxidative capacity. In that respect, Kelley
et al.(14) were the first to suggest that mitochondrial func-
tion may be reduced in T2DM patients. Shortly after,
two independent investigations, using DNA microarrays,
showed a general reduction in genes involved in mito-
chondrial function, both in T2DM as well as in family
history positive insulin-resistant subjects(15,16). On a
more functional level, using 13C and 31P (magnetic reson-
ance spectroscopy), Petersen et al.(7) showed a 40% re-
duction in resting muscle TCA cycle flux in elderly
compared with young controls. The latter was ac-
companied by a reduced saturation transfer between in-
organic phosphate and ATP, which is a reflection of
ATP synthesis rate, suggesting a reduced in vivo mito-
chondrial function upon ageing. We have used a slightly
different magnetic resonance spectroscopy technique to
determine in vivo mitochondrial function and examined
phosphocreatine recovery rate after exercise, assessed
by 31P magnetic resonance spectroscopy(17). Post-exercise
recovery of phosphocreatine is an almost entirely
aerobic-driven process(18), rendering an adequate
measure of in vivo mitochondrial function(19). Using
this technique we found that in vivo mitochondrial func-
tion was reduced in T2DM patients compared with BMI-
matched obese control subjects(17). In addition, we could
show, using high-resolution respirometry, that the
reduced in vivo mitochondrial function was paralleled
by a reduction in intrinsic mitochondrial capacity as evi-
denced by lower state 3 and state U respiration in type 2
diabetic muscle fibres(20). Together, these findings do sug-
gest that mitochondrial function is affected in T2DM
and insulin resistance, and may underlie the accumu-
lation of fat in skeletal muscle. However, it should be
noted that these kinds of studies do not allow us to un-
ravel if a reduced mitochondrial function causes the de-
velopment of diabetes in human subjects. At present
the question if mitochondrial dysfunction is cause or
consequence of diabetes is still an ongoing debate and
reviewed elsewhere (see also(21,22)).
Mitochondria as a target to improve insulin sensitivity
The focus on mitochondrial dysfunction as a potential
cause of insulin resistance and T2DM has also resulted
in a renewed interest of mitochondria as a target to
treat diabetes. It is well known and well described that
physical exercise training is perhaps the single best option
for the prevention and treatment of T2DM. Nielsen
et al.(23) showed that a 10-week aerobic cycling training
in obese, male T2DM patients and age- and
BMI-matched controls indeed improved mitochondrial
content (by ∼40 %) and that this was accompanied by
an increase in insulin sensitivity in both groups. In
2010, we performed an exercise-training intervention
in T2DM patients and BMI- and age-matched obese
controls, and examined mitochondrial function in further
detail. We used a 12-week progressive training pro-
gramme, consisting of twice weekly endurance exercise
training combined with once weekly resistance training
session. We showed that all aspects of mitochondrial
function, including in vivo mitochondrial function using
phosphocreatine recovery rate, intrinsic mitochondrial
function using high-resolution respirometry, and mito-
chondrial content, increased after the 12 weeks train-
ing(24,25), and restored T2DM patients towards control
values. We performed hyperinsulinaemic euglycaemic
clamps to investigate if the training also resulted in
improved insulin sensitivity, and indeed found an im-
provement in skeletal muscle insulin sensitivity, which
was most pronounced in T2DM. In a subset of patients,
we also confirmed the reduced intrinsic mitochondrial
capacity in T2DM patients, which we reported earlier(20),
and showed that mitochondrial respiration in permeabi-
lised muscle fibres was significantly improved and
restored to control levels upon the 12-week training pro-
gramme. These findings are consistent with findings
by Hey-Mogensen et al.(26), and show that exercise train-
ing improves mitochondrial function in parallel with
improvements in insulin sensitivity. However, again,
such studies do not show a causal relationship between
mitochondrial function and insulin sensitivity. We there-
fore investigated if a higher mitochondrial function
indeed could prevent the development of insulin resist-
ance. To this end, we compared endurance-trained
athletes with sedentary, age- and BMI-matched controls.
First, we confirmed that endurance trained athletes
indeed had higher mitochondrial oxidative capacity, as
determined by state 3 and state U respiration in permea-
bilised muscle fibres. We also confirmed that endurance
trained athletes have a higher (muscle) insulin sensitivity.
Next, we tested if the enhanced mitochondrial function
in endurance-trained athletes would also protect
them from the development of lipid-induced insulin re-
sistance. To this end, we infused subjects, during a hyper-
insulinaemic euglycaemic clamp, with high levels of
a TAG emulsion together with heparin, which results
in elevated circulating fatty acids and the development
of insulin resistance within 2–3h after initiating the
lipid infusion(4). Interestingly, whereas lipid infusion
resulted in a ∼70 % reduction in insulin sensitivity in
sedentary controls, only a ∼30 % reduction in insulin sen-
sitivity was observed in endurance trained athletes, sug-
gesting that endurance training indeed partly protects
against the development of lipid-induced insulin
resistance(27).
Taken together, a high mitochondrial function in hu-
man subjects is, at least, associated with improved insulin
sensitivity, and therefore improving mitochondrial
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function may be a useful target to prevent and T2DM
and related metabolic disorders.
Non-exercise mimetics to improve mitochondrial function
Although there is little doubt that exercise training and
regular physical activity is key for the prevention of dia-
betes, most people experience difficulties to strictly follow
a regular exercise programme. Another, but perhaps even
less attractive option to stimulate mitochondrial function
is energy restriction. In human subjects, a study has been
conducted in young overweight volunteers that reduced
energy intake by ∼25 % for 6 months. Subjects were stud-
ied before and after the intervention, and it was found
that indices of obesity and ectopic fat storage were re-
duced after energy restriction. Furthermore, markers of
insulin sensitivity also improved(28,29). The authors then
showed that skeletal muscle markers of mitochondrial
functions such as the transcriptional factor PGC 1α,
mitochondrial transcription factor A and sirtuin 1
(SIRT1) were all increased after energy restriction and
this was accompanied by an increase in mitochondrial
content (as determined by level of mtDNA content)(30).
This human data show that also in human subjects en-
ergy restriction is very effective in improving metabolic
health, and thereby confirms the wealth of earlier rodent
data. In fact, from animals studies it was concluded that
SIRT1, the founding member of sirtuin protein family
of NAD+-dependent deacetylases, may be involved in
the underlying mechanisms of energy-restriction induced
improvements in insulin sensitivity and mitochondrial
function(31). Both exercise training and energy restriction
may mechanistically converge and stimulate the
AMPK–SIRT1–PGC1α axis to enhance mitochondrial
oxidative capacity in muscle. Therefore, a search for
novel stimulators of this pathway was initiated, which
among others resulted in the discovery of resveratrol
(3,5,4′-trihydroxystilbene) as a small molecule activator
of SIRT1(32), most likely via activation of AMPK(33,34).
Can resveratrol improve metabolic health?
Resveratrol was first isolated from the roots of the
poisonous medicinal plant white hellebore (Veratum
grandiflorum O. Loes)(35). In 1992, resveratrol attracted
the attention when the compound was suggested to ex-
plain part of the cardioprotective effects of red
wine, also referred to as the French paradox(36). In
follow-up studies, resveratrol was also shown to have
anti-inflammatory and anti-oxidant properties (reviewed
in(37,38)). In 2003, Howitz et al.(32) identified resveratrol
as a potent SIRT1 activator(39,40), which boosted the
interest in the compound as an energy restriction mi-
metic. They and others also showed that resveratrol
could positively affect longevity in yeast(32), worms(41),
flies(42,43) and in short-lived fish(44).
More recently, interest in resveratrol shifted towards its
potential to affect metabolic health. In 2006, Lagouge
et al.,(40) showed that a high dose of resveratrol
(400mg/kg per d) resulted in, amongothers, improvements
in insulin sensitivity, and a reduction in body weight. The
latter effect might be dose-dependent, as a lower dose of
resveratrol (∼22·5mg/kg per d) was insufficient to result
in weight loss, but it still improved glucose tolerance(39).
The reason for the effect of body weight is not clear, but
it has been shown that at higher dose resveratrol results
in an increase in energy expenditure, despite a reduction
in voluntary exercise, and could underlie the effects on
body weight(40). Work by Dal-Pan et al.(45,46) confirmed
that supplementing resveratrol for 1 year at a dose of
200mg/kg per d to non-human primate Microcebus mur-
inus resulted in an increase in BMR and average daily
energy requirements as well as improvements in metabolic
health(45,46). Together, these and many other rodent data
have suggested a potential for resveratrol to affect meta-
bolic health and urged for studies in human subjects.
A first study that reported effects of resveratrol on
metabolism in human subjects was performed by Elliot
et al.(47). They reported that supplementing T2DM
patients with high doses of resveratrol (2·5 and 5g/d)
for 28d resulted in decreased levels of fasting and post-
prandial glucose and insulin. Brasnyo et al.(48) reported
in 2011 positive effects of 4 weeks supplementation of a
low dose of 5mg resveratrol to T2DM patients on insulin
sensitivity, as determined by homeostatic model assess-
ment (HOMA)-index, effects that were accompanied by
a reduction in markers of oxidative stress. Crandall
et al.(49) examined in a small pilot study the effect of
4 weeks resveratrol treatment, with high doses of 1–2g/
d on glucose homoeostasis in subjects with an impaired
glucose tolerance, and reported that resveratrol was
able to reduce postprandial glucose levels. These effects
could not be confirmed by Ghanim et al.(50), who
reported no beneficial effects of a 6-week intervention
with an extract containing 40mg resveratrol on
HOMA-index, performed in healthy volunteers.
Given these promising effects in first human trials, we
decided to perform a detailed characterisation of the
metabolic effects of resveratrol in obese human subjects.
Thus, we supplemented healthy middle-aged, obese men
with normal glucose tolerance with 150mg resveratrol/d
for 30d. We did so in a placebo-controlled, randomised
and double-blinded crossover design. After 30d of
resveratrol supplementation, we found that fasting
plasma levels of glucose and insulin were slightly, but
significantly reduced compared to after placebo sup-
plementation, resulting in an improvement in HOMA-
index(51). We reported no adverse effects of resveratrol,
and also found reductions in plasma TAG and alanine
aminotransferase levels, the latter being a marker for
liver function. Also, a significant decrease in blood press-
ure was observed. Because we were interested in the ef-
fects of resveratrol on energy and mitochondrial
metabolism, we further studied these subjects in so-called
whole-body room calorimeters. In these respiration
chambers, we found that 30d resveratrol had a signifi-
cant effect on sleeping metabolic rate, resulting in a de-
crease in energy metabolism. This finding is in contrast
with the increase in energy expenditure that is observed
in rodents, but consistent with the effects of energy re-
striction that are reported in human subjects(28,29). We
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next turned our focus on skeletal muscle and examined
mitochondrial metabolism in skeletal muscle biopsies
taken after the intervention. Gene-set enrichment analy-
sis of DNA microarrays performed on muscle tissue
revealed that resveratrol activated similar pathways in
human subjects compared with mice, as mitochondrial
pathways related to ATP production and oxidative phos-
phorylation were up-regulated and inflammatory path-
ways were down-regulated. Moreover, we could show
that, as in rodents, resveratrol acts on the AMPK–
SIRT1–PGC1 axis and had beneficial effects on mito-
chondrial respiration as determined by high-resolution
respirometry. Given this increase in mitochondrial oxi-
dative capacity and the hint towards improved insulin
sensitivity, we tested if resveratrol supplementation also
resulted in the expected decrease in ectopic fat storage.
Indeed, liver fat content was reduced after 30d resvera-
trol supplementation(51). However, very intriguingly, we
found a pronounced increase in IMCL content, both in
type 1 and type 2 diabetic muscle fibres.
Taken together, we showed that resveratrol had benefi-
cial effects on metabolic health in obese, middle-aged
men but also increases IMCL. Whether this increase in
IMCL is a detrimental effect of resveratrol needs further
study (see later). Please note that since our study was
published, at least two other resveratrol trials were pub-
lished that did not confirm beneficial effects of resvera-
trol(52,53). The reason for the discrepancies between
studies may lie in methodological differences, and has
been recently reviewed by us and is therefore out of the
scope of this review(54).
Is resveratrol an exercise mimetic?
One of the most intriguing findings of our resveratrol
trial was the finding that IMCL was markedly increased
after 30d resveratrol. As outlined earlier, increased
IMCL is found to negatively associate with insulin sensi-
tivity, at least in sedentary and/or obese subjects. Given
that all other markers of metabolic health, including cir-
culating TAG improved, and that fat oxidative capacity
was enhanced, it is not realistic to assume that this in-
crease in IMCL is due to excessive fat storage as
observed in the obese state. Interestingly, endurance-
trained athletes, who are very insulin sensitive, are also
characterised by elevated IMCL levels(55). This dis-
sociation between IMCL levels and insulin sensitivity is
referred to as the athletes paradox(55) and suggests that
with training lipid droplet may be stored in the muscle
to serve as rapid available substrate fuel during exercise.
Since resveratrol has many metabolic health benefits that
are similar to those observed with endurance training, in-
cluding reductions in blood pressure, energy metabolism,
blood glucose, TAG and insulin levels and improvements
in mitochondrial metabolism, it is tempting to speculate
that resveratrol may actually have exercise-like effects.
Recently, we showed that exercise not only resulted in
an increase in mitochondrial metabolism but also
resulted in the up-regulation of a programme of genes
involved in lipid droplet storage in muscle(56). We showed
that these effects may be explained by exercise-induced
activation of the transcriptional coactivator PGC1α, as
transgenic PGC1α mice and experiments in primary
myotubes in which PGC1α was overexpressed, showed
that this transcription factor is not only involved in sti-
mulating mitochondrial metabolism(57) but also in the ac-
tivation of a lipid droplet gene programme. Furthermore,
by comparing endurance-trained athletes with sedentary
young human subjects, we could confirm that this lipid
droplet gene programme was also enhanced in trained
human subjects(56), illustrating that not only IMCL is
increased in trained athletes, but that also the machinery
to efficiently store and liberate lipids from these lipid dro-
plets is enhanced by training. Interestingly, we have re-
cently shown for two of the major players in the lipid
droplet programme, perilipins (PLIN) 2 and 5, that
they are essential for lipid storage in skeletal muscle
cells(58,59). Thus, both the overexpression of PLIN2
in C2C12 muscle cells as well as the overexpression of
PLIN2 or PLIN5 in skeletal muscle of adult rats
in vivo resulted in enhanced accumulation of intramyo-
cellular lipids. Despite this fat accumulation PLIN2/5
overexpression did not result in the development of
lipid-induced insulin resistance, suggesting that storage
of lipid droplets in skeletal muscle does not need to ham-
per insulin sensitivity when also the machinery for proper
lipid droplet dynamics is enhanced(58,59). Consistently, it
was previously shown that acute exercise is able to over-
come lipid-induced insulin resistance by enhancing the
capacity to store TAG in muscle(60). Whether the effect
of resveratrol on IMCL content in human subjects is
also due to PGC1α-induced activation of the lipid drop-
let gene programme and results in efficient and safe sto-
rage of lipid in muscle is a tempting speculation, but
needs further investigation. Also the longer-term effects
of this increase in IMCL, and the question if resveratrol
acutely improves skeletal muscle insulin sensitivity in
human subjects, still needs to be determined, and such
studies are currently underway.
Relevant to the question if resveratrol could be seen as
an exercise mimetic, a recent paper was published in
which it was found that resveratrol blunted the positive
effects of exercise training on cardiovascular health in
older men. That is, when high-intensity exercise training
for 8 weeks was combined with 250mg resveratrol/d
training effects on blood lipids, blood pressure and maxi-
mal aerobic capacity were blunted when compared with
the same training without resveratrol(61). However, care-
ful examination of the data reported shows that not all
examined parameters were blunted by resveratrol and
that actually several parameters were improved after
resveratrol when compared with placebo, suggesting
that the conclusion may be somewhat exaggerated.
Conclusions and perspective
There is ample evidence supporting the notion that
improving mitochondrial function can have beneficial
effects on metabolic health and may prevent some of
the age-related metabolic disturbances that may
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ultimately lead to T2DM and CVD. From pre-clinical
research, it is evident that resveratrol, and other com-
pounds affecting the AMPK–SIRT1–PGC1 axis, have
great potential to improve mitochondrial metabolism in
a non-exercise manner. Whether such compounds also
have therapeutic potential in human subjects is much
too early to draw definitive conclusions, and many clini-
cal trials will be needed to test this hypothesis. Designing
such studies will not be easy as many factors that may de-
termine the outcome of such trials are still unknown, but
include dosing and timing of resveratrol, target popu-
lation, selection of outcome parameters, etc. However,
given that there are currently only very few successful
non-exercise approaches to combat metabolic diseases,
it is worth making the effort to investigate the true poten-
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